How do oral COPD treatments compare?
Investigators assessed new users of azithromycin and roflumilast with active COPD.
-
By
-
Kathryn Wighton
-
September 2, 2026
-
Clinical Scorecard: How do oral COPD treatments compare?
At a Glance
| Category | Detail |
|---|
| Condition | Chronic Obstructive Pulmonary Disease (COPD) |
| Key Mechanisms | Comparison of azithromycin and roflumilast in reducing exacerbation rates. |
| Target Population | Patients aged 40 years and older with active COPD. |
| Care Setting | Outpatient and inpatient settings for COPD management. |
Key Highlights
- Azithromycin associated with a 17% lower likelihood of first moderate or severe exacerbation compared to roflumilast.
- Model-based 1-year risks: 60% for azithromycin vs. 67% for roflumilast.
- Moderate exacerbations defined as requiring 5 to 14 days of oral glucocorticoid treatment.
- Severe exacerbations defined as requiring COPD-related hospitalization.
- Study limitations include short follow-up and potential misclassification in claims data.
Guideline-Based Recommendations
Diagnosis
- Active COPD defined by outpatient or inpatient claims and maintenance inhaler fills.
Management
- Consider azithromycin for patients without a history of COPD hospitalization.
Monitoring & Follow-up
- Monitor exacerbation rates and treatment adherence.
Risks
- Potential for residual confounding and misclassification in claims data.
Patient & Prescribing Data
Patients aged 40 years and older with active COPD.
Azithromycin may be preferred for reducing exacerbation risk in certain patient subgroups.
Clinical Best Practices
- Utilize propensity score matching for treatment comparisons.
- Assess patient history of COPD hospitalization when selecting treatment.
Related Resources & Content
